Having finally unveiled a long-awaited set of proposals to overhaul the EU’s pharmaceutical legislation, the European Commission has pointed to reforms that will help promote generic and biosimilar competition in Europe, including simplified marketing authorization procedures, measures that will allow for faster off-patent competition, and harmonization of the way the Bolar exemption functions across the EU.
As part of the proposals, the Commission has also suggested changes to regulatory data protection periods for originators that will...